-
Detailed Analysis Generate Full Report Add to Watchlist
Values as of: 2024-03-28
Values as of: 2024-03-28
The investment seeks to provide investment returns that closely correspond to the price and yield performance of the Nasdaq Composite Index?. The fund normally invests at least 80% of assets in common stocks included in the index. It uses statistical sampling techniques that take into account such factors as capitalization, industry exposures, dividend yield, price/earnings (P/E) ratio, price/book (P/B) ratio, and earnings growth to create a portfolio of securities listed in the Nasdaq Composite Index that have a similar investment profile to the entire index.
Company Website : www.fidelity.com
Currency: USD
Country : USA
Inception Date: 21/10/2013
Primary Benchmark: MSCI USA IMI/Health Care GR USD
Primary Index: MSCI ACWI NR USD
Gross Expense Ratio: 0.12%
Management Expense Ratio: 0.08 %
N/A
N/A
| Symbol | Company Name | Allocation |
|---|---|---|
| LLY | Eli Lilly and Company | 10.38 % |
| UNH | UnitedHealth Group Incorporated | 7.59 % |
| JNJ | Johnson & Johnson | 5.97 % |
| MRK | Merck & Company Inc | 5.44 % |
| ABBV | AbbVie Inc | 4.97 % |
| TMO | Thermo Fisher Scientific Inc | 3.62 % |
| ABT | Abbott Laboratories | 3.15 % |
| DHR | Danaher Corporation | 2.88 % |
| PFE | Pfizer Inc | 2.46 % |
| AMGN | Amgen Inc | 2.42 % |
N/A
N/A
| Symbol | Name | Mer | Price(Change) | Market Cap |
|---|---|---|---|---|
| XLV | Health Care Select Sector SPDR.. | 0.13 % |
N/A |
USD 37.76B |
| VHT | Vanguard Health Care Index Fun.. | 0.10 % |
N/A |
USD 16.98B |
| XBI | SPDR® S&P Biotech ETF | 0.35 % |
N/A |
USD 7.05B |
| IHI | iShares U.S. Medical Devices E.. | 0.43 % |
N/A |
USD 5.55B |
| IXJ | iShares Global Healthcare ETF | 0.46 % |
N/A |
USD 4.11B |
| IYH | iShares U.S. Healthcare ETF | 0.43 % |
N/A |
USD 3.23B |
| FXH | First Trust Health Care AlphaD.. | 0.63 % |
N/A |
USD 1.33B |
| FBT | First Trust NYSE Arca Biotechn.. | 0.57 % |
N/A |
USD 1.08B |
| IHF | iShares U.S. Healthcare Provid.. | 0.43 % |
N/A |
USD 0.82B |
| IHE | iShares U.S. Pharmaceuticals E.. | 0.42 % |
N/A |
USD 0.69B |
N/A
| Market Performance vs. Industry/Classification (Health) | Market Performance vs. Exchange (NYSE Arca) | ||||||
| Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
| YTD | |||||||
| Capital Gain | 7.85% | 68% | D+ | 68% | D+ | ||
| Dividend Return | 0.37% | 77% | C+ | 22% | F | ||
| Total Return | 8.22% | 68% | D+ | 67% | D+ | ||
| Trailing 12 Months | |||||||
| Capital Gain | 14.81% | 73% | C | 61% | D- | ||
| Dividend Return | 1.13% | 68% | D+ | 14% | F | ||
| Total Return | 15.94% | 68% | D+ | 57% | F | ||
| Trailing 5 Years | |||||||
| Capital Gain | 56.79% | 80% | B- | 73% | C | ||
| Dividend Return | 6.83% | 84% | B | 24% | F | ||
| Total Return | 63.62% | 80% | B- | 71% | C- | ||
| Average Annual (5 Year Horizon) | |||||||
| Capital Gain | 9.34% | 73% | C | 71% | C- | ||
| Dividend Return | 10.38% | 77% | C+ | 68% | D+ | ||
| Total Return | 1.04% | 85% | B | 27% | F | ||
| Risk Return Profile | |||||||
| Volatility (Standard Deviation) | 12.44% | 82% | B | 75% | C | ||
| Risk Adjusted Return | 83.47% | 82% | B | 96% | N/A | ||
| Market Capitalization | 0.58B | 73% | C | 69% | C- | ||
| Target Price Action | Rating Action | Analyst | Rating | Price | Date |
|---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.
The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
